Mab Drugs
Apr 02, 2012 at 09:46 | Source: Reuters
Aug 13, 2008 at 08:19 | Source: Business Line
Jul 11, 2008 at 08:27 | Source: Business Line
Photos »
/ 
Related News »
drugs. Forecasts and trends are gleaned from industry sources, analyst reports, and company forecasts, as well as from assessment of available and emerging technologies. The report develops forecasts for sales of the mAb market by individual ...
May 23, 2012 at 10:51 | Source: TheStreet.com
The aim of this report is to provide a range of information -- from detailed analysis through industry trends -- to quantify and qualify the rapidly growing market for therapeutic monoclonal antibody (mAb) drugs. Forecasts and trends are gleaned from ...
May 14, 2012 at 11:37 | Source: Transworld News
Aging Population, Growing Awareness and Novel Therapeutics Drives the Global Osteoporosis … - YAHOO!
Key product segments analyzed include Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others (including Anabolic/Bone-Forming agents such as Tereparatide). Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
May 14, 2012 at 09:36 | Source: YAHOO!
"Despite the current drugs on the market, there remain a number of unmet needs ... an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (MAb). This is a targeted treatment that identifies and attacks specific cancer cells without harming ...
May 17, 2012 at 06:40 | Source: science20.com
By this point, Humira will represent 11.1% of the mAb/fusion protein market and 6.0% of the biological drug market overall. The drug remains patent protected until 2017 in the US and 2018 in the EU. After reaching a high of $9.7bn in 2017, Humira's ...
May 17, 2012 at 05:29 | Source: Transworld News
The current drugs have been priced at $60,000 to $120,000 per therapy ... The most important thing is the newly approved drug therapy, immunotherapy Yervoy which is known as CTLA mAb. In animal studies we’ve shown that we’ve synergy with our therapy ...
May 17, 2012 at 00:07 | Source: Seekingalpha.com
The request would effectively shield Abbott’s mAb therapeutic and biggest-selling treatment ... remaining as a maker of medical equipment and generic drugs. Kalyan R. Anumala, Ph.D., senior director of Therapeutic Proteins, suggests that ...
May 15, 2012 at 20:26 | Source: Genetic Engineering News
"Despite the current drugs on the market, there remain a number of unmet needs ... an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (MAb). This is a targeted treatment that identifies and attacks specific cancer cells without harming ...
May 17, 2012 at 02:01 | Source: Newswiretoday.com
The products developed using F-star's technology are unique in their modularity, while leveraging the strengths of conventional monoclonal antibody drugs. This allows very fast generation of bispecific antibody drugs, as well as minimised ...
May 14, 2012 at 05:54 | Source: msnbc.com
It pushes up against the size limits of common techniques like GC-MS, but it remains squarely in the realm of synthetic drugs because it is commonly made ... We're about to see the first biosimilar mAb go up for approval, and there are already approved ...
May 15, 2012 at 23:54 | Source: Genetic Engineering News